Adjuvant nivolumab (NIVO) versus ipilimumab (IPI) in resected stage III/IV melanoma: 3-year efficacy and biomarker results from the phase III CheckMate 238 trial

Bibliographic Details
Main Authors:	Weber, J, Del Vecchio, M, Mandala, M, Gogas, H, Arance, A, Dalle, S, Cowey, C, Schenker, M, Grob, J, Chiarion-Sileni, V, Marquez-Rodas, I, Butler, M, Maio, M, Middleton, M, Tang, T, Saci, A, De Pril, V, Lobo, M, Larkin, J, Ascierto, P
Format:	Conference item
Language:	English
Published:	Oxford University Press 2019

Similar Items